Altered daytime fluctuation pattern of plasminogen activator inhibitor 1 in type 2 diabetes patients with coronary artery disease: A strong association with persistently elevated plasma insulin, increased insulin resistance, and abdominal obesity

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  Lalić, Katarina ^a,b   Jotić, Aleksandra ^a,b   Rajković, Nataša ^a,b   Singh, Sandra ^a   Stošić, Ljubica ^a   Popović, Ljiljana ^a   Lukić, Ljiljana ^a,b   Miličić, Tanja ^a,b   Seferović, Jelena P ^a,b   Maćešić, Marija ^a   Stanarčić, Jelena ^a   Čivčić, Milorad ^a   Kadić, Iva ^a   Lalić, Nebojša M ^a,b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SULFONYLUREA;

ABDOMINAL OBESITY; ADULT; ANGINA PECTORIS; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; DRUG BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HIP CIRCUMFERENCE; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; UNSTABLE ANGINA PECTORIS; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

EID: 84930648886     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/390185     Document Type: Article

References (46)

1. E.D. Sprengers and C.Kluft, "Plasminogen activator inhibitors," Blood, vol. 69, no. 2, pp. 381-387, 1987.
2. D. J. Schneider and B. E. Sobel, "PAI-1 and diabetes: a journey fromthe bench to the bedside," Diabetes Care, vol. 35,no. 10, pp. 1961-1967, 2012.
3. A. Hamsten, G.Walldius, A. Szamosi et al., "Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction," The Lancet, vol. 2, no. 8549, pp. 3-9, 1987.
4. P. Tretjakovs, A. Jurka, I. Bormane et al., "Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina," Clinica Chimica Acta, vol. 413, no. 1-2, pp. 25-29, 2012.
5. B. Erzen and M. Šabovič, "In young post-myocardial infarction male patients elevated plasminogen activator inhibitor-1 correlates with insulin resistance and endothelial dysfunction," Heart and Vessels, vol. 28, no. 5, pp. 570-577, 2013.
6. I. Juhan-Vague, M.-C. Alessi, A. Mavri, and P. E. Morange, "Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk," Journal of Thrombosis and Haemostasis, vol. 1, no. 7, pp. 1575-1579, 2003.
7. K. Landin, L. Stigendal, E. Eriksson et al., "Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1," Metabolism, vol. 39, no. 10, pp. 1044-1048, 1990.
8. C. S. Coffey, F.W. Asselbergs,P.R.Hebert et al., "The association of themetabolic syndrome with PAI-1 and t-PA levels," Cardiology Research and Practice, vol. 2011, Article ID 541467, 8 pages, 2011.
9. B. E. Sobel, J. Woodcock-Mitchell, D. J. Schneider, R. E. Holt, K. Marutsuka, and H. Gold, "Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence," Circulation, vol. 97, no. 22, pp. 2213-2221, 1998.
10. A. Pandolfi, D. Cetrullo, R. Polishuck et al., "Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 8, pp. 1378-1382, 2001.
11. T. K. Nordt, H. Sawa, S. Fujii, and B. E. Sobel, "Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo," Circulation, vol. 91,no. 3, pp. 764-770, 1995.
12. A. Pandolfi, A.Giaccari, C. Cilli et al., "Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat," Acta Diabetologica, vol. 38, no. 2, pp. 71-76, 2001.
13. F. Carmassi, M.Morale, L. Ferrini et al., "Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjects," The American Journal ofMedicine, vol. 107, no. 4, pp. 344-350, 1999.
14. S. Fendri, B. Roussel, B. Lormeau, B. Tribout, and J.-D. Lalau, "Insulin sensitivity, insulin action, and fibrinolysis activity in nondiabetic and diabetic obese subjects," Metabolism: Clinical and Experimental, vol. 47, no. 11, pp. 1372-1375, 1998.
15. V. Grimaudo, J. Hauert, F. Bachmann, and E. K. O. Kruithof, "Diurnal variation of the fibrinolytic system," Thrombosis and Haemostasis, vol. 59, no. 3, pp. 495-499, 1988.
16. I. Juhan-Vague, M. C. Alessi, D. Raccah et al., "Daytime fluctuations of plasminogen activator inhibitor 1 (PAI-1) in populations with high PaI-1 levels,"Thrombosis and Haemostasis, vol. 67, no. 1, pp. 76-82, 1992.
17. F. A. J. L. Scheer and S. A. Shea, "Human circadian system causes amorning peak in prothrombotic plasminogen activator inhibitor-1 (PAI-1) independent of the sleep/wake cycle," Blood, vol. 123, no. 4, pp. 590-593, 2014.
18. F. Andreotti, G. J. Davies, D. R. Hackett et al., "Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke," American Journal of Cardiology, vol. 62, no. 9, pp. 635-637, 1988.
19. P.Angleton, W. L. Chandler, and G. Schmer, "Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1)," Circulation, vol. 79, no. 1, pp. 101-106, 1989.
20. World Health Organization, "Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation," Tech. Rep., World Health Organization, 2006.
21. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, "Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man," Diabetologia, vol. 28, no. 7, pp. 412-419, 1985.
22. R. B. Francis Jr., D. Kawanishi, T. Baruch, P. Mahrer, S. Rahimtoola, and D. I. Feinstein, "Impaired fibrinolysis in coronary artery disease," American Heart Journal, vol. 115, no. 4, pp. 776-780, 1988.
23. K. Huber, D. Rosc, I. Resch et al., "Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction," Thrombosis and Haemostasis, vol. 60, no. 3, pp. 372-376, 1988.
24. I. Juhan-Vague, M. C. Alessi, P. Joly et al., "Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response," Arteriosclerosis, vol. 9, no. 3, pp. 362-367, 1989.
25. B. O. Olofsson, G. Dahlen, and T. K. Nilsson, "Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease," European Heart Journal, vol. 10, no. 1, pp. 77-82, 1989.
26. S. C. L. Gough, P. J. S. Rice, L. McCormack, C. Chapman, and P. J. Grant, "The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed Type 2 diabetes mellitus," DiabeticMedicine, vol. 10, no. 7, pp. 638-642, 1993.
27. L. J. Garcia Frade, H. de la Calle, M. C. Torrado, J. I. Lara, L. Cuellar, and A. Garcia Avello, "Hypofibrinolysis associated with vasculopathy in non insulin dependent diabetes mellitus," Thrombosis Research, vol. 59, no. 1, pp. 51-59, 1990.
28. C.Kluft, A. F. H. Jie, D. C. Rijken, and J. H. Verheijen, "Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1)," Thrombosis and Haemostasis, vol. 59, no. 2, pp. 329-332, 1988.
29. J. E.Muller, P. H. Stone, Z. G. Turi et al., "Circadian variation in the frequency of onset of acutemyocardial infarction," The New England Journal ofMedicine, vol. 313, no. 21, pp. 1315-1322, 1985.
30. R. Kanth, S. Ittaman, and S. Rezkalla, "Circadian patterns of ST elevation myocardial infarction in the new millennium," Clinical Medicine & Research, vol. 11, no. 2, pp. 66-72, 2013.
31. T. Masuda, H. Ogawa, Y. Miyao et al., "Circadian variation in fibrinolytic activity in patients with variant angina," British Heart Journal, vol. 71, no. 2, pp. 156-161, 1994.
32. D. J. Loskutoff, J. A. VanMourik, L. A. Erickson, and D. Lawrence, "Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells," Proceedings of the NationalAcademy of Sciences of theUnited States ofAmerica, vol. 80, no. 10, pp. 2956-2960, 1983.
33. E. D. Sprengers, H. M. G. Princen, T. Kooistra, and V. W. M. van Hinsbergh, "Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2," The Journal of Laboratory and Clinical Medicine, vol. 105, no. 6, pp. 751-758, 1985.
34. M. C. Alessi, I. Juhan-Vague, T. Kooistra, P. J. Declerck, and D. Collen, "Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2," Thrombosis and Haemostasis, vol. 60, no. 3, pp. 491-494, 1988.
35. D. J. Schneider, P. M. Absher, and M. A. Ricci, "Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells," Circulation, vol. 96, no. 9, pp. 2868-2876, 1997.
36. P. J. Grant, E. K. O. Kruithof, C. P. Felley, J. P. Felber, and F. Bachmann, "Short-terminfusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man," Clinical Science, vol. 79, no. 5, pp. 513-516, 1990.
37. B. J. PotterVan Loon,A.C.W.De Bart, J. K. M. Radder Frolich, C. Kluft, and A. E. Meinders, "Acute exogenous hyperinsulinaemia does not result in elevation of plasma plasminogen activator inhibitor-1 (PAI-1) in humans," Fibrinolysis, vol. 4, no. 2, pp. 93-94, 1990.
38. S. G. Wannamethee, G. D. O. Lowe, A. G. Shaper, A. Rumley, L. Lennon, and P. H.Whincup, "Insulin resistance, haemostatic and inflammatory markers and coronary heart disease risk factors in type 2 diabetic men with and without coronary heart disease," Diabetologia, vol. 47, no. 9, pp. 1557-1565, 2004.
39. A. Natali, E. Toschi, S. Baldeweg et al., "Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes," Diabetes, vol. 55, no. 4, pp. 1133-1140, 2006.
40. I. Juhan-Vague, C. Roul, M. C. Alessi, J. P. Ardissone, M. Heim, and P. Vague, "Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients-relationship with plasma insulin," Thrombosis and Haemostasis, vol. 61, no. 3, pp. 370-373, 1989.
41. I. Mertens, I. Lemieux, A. Verrijken, J.-P. Després, and L. F. Van Gaal, "PAI-1 activity, but not fibrinogen or vonWillebrand factor, is inversely related to LDL particle size in type 2 diabetes," Diabetes/Metabolism Research and Reviews, vol. 24, no. 2, pp. 141-147, 2008.
42. L. Liu, S.-P. Zhao, T. Wen, H.-N. Zhou, M. Hu, and J.-X. Li, "Postprandial hypertriglyceridemia associated with inflammatory response and procoagulant state after a high-fat meal in hypertensive patients," Coronary Artery Disease, vol. 19, no. 3, pp. 145-151, 2008.
43. M.-C. Alessi and I. Juhan-Vague, "PAI-1 and the metabolic syndrome: links, causes, and consequences," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 10, pp. 2200-2207, 2006.
44. P. Vague, I. Juhan-Vague, M. F. Aillaud et al., "Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects," Metabolism, vol. 35, no. 3, pp. 250-253, 1986.
45. L. M. Belalcazar, C. M. Ballantyne, W. Lang et al., "Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings fromthe look AHEAD study," Arteriosclerosis,Thrombosis, and Vascular Biology, vol. 31, no. 7, pp. 1689-1695, 2011.
46. D. Bastelica, P. Morange, B. Berthet et al., "Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 1, pp. 173-178, 2002.